CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
4 mL injection of Ampion +1 morebiological
Likely dose
4 mL injection of Ampionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02184156
NCT02184156Phase 2Completed

A Prospective Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of Three Intra-articular Injections of Ampion™ (4 mL) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee

Ampio Pharmaceuticals. Inc.·interventional·Posted Jul 9, 2014·Updated Sep 30, 2022

In Brief

A Phase 2 clinical trial evaluating 4 mL injection of Ampion and 4 mL injection of Placebo for Osteoarthritis of the Knee. Completed, enrolled 47 participants across 1 site.

Detailed Summary

Phase 1 will evaluate the safety of 3 intra-articular injections of Ampion™ administered 2 weeks apart to adults with osteoarthritis of the knee. In the absence of serious drug-related Adverse Events (AEs) of unanticipated drug-related AEs, enrollment will be initiated in Phase 2 of the study. Phase 2 will evaluate the efficacy of 3 intra-articular injections, given 2 weeks apart, of Ampion™ in Adults with pain due to osteoarthritis of the knee.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 9, 2014
Enrollment StartJun 1, 2014
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.0 years ago

Interventions

4 mL injection of Ampionbiological

4 mL injection of Ampion

4 mL injection of Placebodrug